Portal de Periódicos da CAPES

Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease

2009; Oxford University Press; Volume: 15; Issue: 8 Linguagem: Inglês

10.1002/ibd.20899

1536-4844

A. Cassinotti, Simon Travis,

Microscopic Colitis

BackgroundInfliximab (IFX) is a chimeric (mouse/human) anti-TNF-alpha monoclonal antibody approved for the treatment of refractory luminal and fistulizing Crohn's disease (CD). It is a source of potential immunogenicity for humans, with the occurrence of anti-infliximab antibodies (ATIs), which are thought to interfere with the pharmacodynamics and/or pharmacokinetics of the compound. It remains unclear whether ATIs have any clinical importance for drug efficacy or safety. We review studies specifically evaluating the incidence of ATIs in CD and their impact on the efficacy and safety of IFX.